Treatment With Lorcaserin for Cocaine Use: The TLC Study

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against HTR2C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

• 2024-07-24Phase 3 first posted: Mahidol University, Olanzapine 2.5 MG + Olanzapine 5 MG (NCT06517199)
• 2024-07-15Phase 3 first posted: Qingdao Central Hospital, Megestrol Acetate and olanzapine + Starch powder 50 mg (NCT06500234)
• 2024-07-01Phase 3 first posted: Louisiana State University Health Sciences Center Shreveport, Lumateperone 42 mg + Risperidone 2 mg (NCT06482554)
• 2024-06-13Results posted on the registry: Corcept Therapeutics, Miricorlilant + Miricorlilant (NCT04524403)
• 2024-05-28Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Intranasal midazolam + Intramuscular loxapine (NCT05324852)
• 2024-05-22Results posted on the registry: Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo SL Tablet (NCT03062540)
• 2024-05-22Also stopped (terminated): Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo SL Tablet (NCT03062540)
• 2024-05-21Results posted on the registry: Food and Drug Administration (FDA), Oxycodone and Midazolam + Oxycodone, Paroxetine, and Quetiapine (NCT04310579)
• 2024-05-06Also stopped (withdrawn): Mayo Clinic, Olanzapine + Placebo Administration (NCT05403580)
• 2024-04-23Also stopped (terminated): Mylan Pharmaceuticals Inc, Olanzapine Tablets 20 mg + Zyprexa® Tablets 20 mg (NCT00647972)
• 2024-04-19Also stopped (terminated): Marubeni Pharmaceuticals (Suzhou) Co., Ltd., Lurasidone (NCT05213143)
• 2024-03-29Phase 3 first posted: Qinghai Red Cross Hospital, Olanzapine 2.5 MG + Standard anti-tumor treatment (NCT06338683)
• 2024-03-27Phase 3 first posted: Foundation for Advancing Veterans' Health Research, Quetiapine Fumarate + TAU (NCT06333990)
• 2024-03-26Phase 3 first posted: Fudan University, Netupitant / Palonosetron Oral Capsule [Akynzeo] + Olanzapine (NCT06331520)
• 2024-03-18Phase 3 first posted: Feixue Song, Antiemetic Therapy + Antiemetic Therapy (NCT06314906)
• 2024-02-28Also stopped (withdrawn): Eurofarma Laboratorios S.A., FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo + etoricoxib 90 mg (Arcoxia®) +FDC placebo (NCT05683574)
• 2024-02-05Results posted on the registry: University of Washington, Trazodone + Placebo (NCT03534284)
• 2024-01-31Results posted on the registry: Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
• 2024-01-31Also stopped (terminated): Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
• 2024-01-22Results posted on the registry: Rush University Medical Center, o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1 + Olanzapine10 mg orally daily on Days -1,0,+1 and +2 (NCT02939287)
• 2024-01-10Phase 3 first posted: M.D. Anderson Cancer Center, Olanzapine + Olanzapine (NCT06200181)
• 2024-01-10Phase 3 first posted: Jiuda Zhao, Standard antiemetic treatment + Standard antiemetic treatment (NCT06200168)
• 2023-12-18Phase 3 first posted: Corey Hawes, Cyproheptadine + Olanzapine (NCT06175273)
• 2023-12-11Also stopped (withdrawn): Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo (NCT05372887)
• 2023-10-02Phase 3 first posted: Lone Baandrup, Melatonin + Quetiapine (NCT06062953)

What is not public

• Internal portfolio and board discussions
• Unpublished trial data and interim analyses
• Terms of any partner or licence decision